Clinical Trial Update: A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate the relative bioavailability and intra-subject variability of two lots of E5501 40 mg tablets in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• E5501

Snippet

Sponsor: Eisai Inc. | Conditions: Idiopathic Thrombocytopenia Purpura | Phase 1 | Status: COMPLETED